23-valent pneumococcal polysaccharide vaccine (Merck Sharp & Dohme)

23价肺炎球菌多糖疫苗 (默沙东）

Report date: 2022/09/14 15:49:41

Base Information

Drug Name23-valent pneumococcal polysaccharide vaccine (Merck Sharp & Dohme)
Drug Alias NamePNEUMOVAX 23Pneumovax 23纽莫法ProDiax-23PPSV23
ClassificationVaccines > National Immunization Program > Non-immunization program vaccine(Class II)Vaccines > Vaccine type > Multivalent vaccineVaccines > Biological material > Bacterial vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsAzoospermiaMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis +[18] 
Global Approved IndicationsPneumonia, Bacterial
Approved Indications in ChinaPneumonia, Bacterial
Original Approved Country/TerritoryUnited States
Original Approved Date1983/06/30
Country/TerritoryUnited StatesSwedenAustralia +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of California DavisMerck Sharp & Dohme CorpCelgene Corp
Inactive CompaniesGlaxosmithkline PlcMenzies School Of Health ResearchThe University Of Toledo Health Science Campus +[7] 
Active IndicationsAzoospermiaMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis +[4] 
Inactive IndicationsTympanic Membrane PerforationOtitis Media with EffusionOtitis Media +[14] 

Other Information

ATC CodeJ07AL02
Related LinksN/A